Discussing Immunotherapy on The Bio Report Podcast

 

 

December 21, 2017 --

 

Brad Loncar, founder of the Loncar Cancer Immunotherapy Index, is recently back from the American Society of Hematology meeting in Atlanta. This is one of the main events for cancer immunotherapy given how CAR-T cellular immunotherapy has made such strong inroads against blood cancers. 

 

Since ASH is a bookend for the year, this is a perfect time to look back on 2017 and discuss what is ahead for the field of cancer immunotherapy in 2018. Brad was invited to join Daniel S. Levine of The Bio Report podcast to do just that. We are thankful for the generous opportunity. Please have a listen below if you would like to hear more about the state of play for immunotherapy headed into the new year.

 

Opinions expressed are those of the author or cancer researchers who are interviewed, are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice. 

 

We hope you enjoy the program.   

 

The Year in Immuno-Oncology and What to Watch in 2018: It’s that time of year when we begin to look back and think ahead. Starting with this week’s interview, we begin a three-part review-preview series to discuss the year in biotech and what to look for in 2018. In 2017, there were exciting developments in the area of immune-oncology with the approval of the first Car-T therapies and Gilead’s acquisition of Kite Pharma. As the year approached the finish line, investors got to view data from a range of studies at the American Society of Hematology meeting in Atlanta, setting the stage for 2018 when data from studies looking at combinations of immunotherapies will be closely watched. We spoke to Brad Loncar, CEO of Loncar investments, about the state of immunotherapies, what caught his attention at the ASH meeting, and what he’ll be watching in 2018. 

Loncar Investments, LLC : P.O Box 15072, Lenexa, KS  66285 : 913-871-5007 : Not investment advice or a solicitation to buy or sell securities